SCHEMBL2186950

SCHEMBL2186950

O=C(NN1CC2CCCC2C1)c1nn(-c2ccc(Cl)cc2Cl)c2c1CCCc1sc(Cl)cc1-2

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 12/20 0.65
▸ CNR2 P34972 12/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL495960 0.88 CNR2 (0.74) CNR1CNR2
SCHEMBL2186133 0.87 CNR1 (0.63) CNR1CNR2
SCHEMBL496518 0.85 CNR2 (0.72) CNR1CNR2
SCHEMBL496561 0.84 CNR2 (0.74) CNR1CNR2
SCHEMBL495971 0.84 CNR2 (0.74) CNR1CNR2
SCHEMBL2186953 0.83 CNR2 (0.53) CNR1CNR2
SCHEMBL496092 0.83 CNR2 (0.53) CNR1CNR2
SCHEMBL2715501 0.83 CNR1 (0.67) CNR1CNR2
SCHEMBL2185805 0.82 CNR1 (0.63) CNR1CNR2
SCHEMBL496212 0.80 CNR2 (0.73) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030345-B2 Tricyclic pyrazole derivatives as cannabinoid receptor modulators CADILA HEALTHCARE LIMITED (IN) 2011-10-04 — — US claimed
EP-2343302-A1 TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CADILA HEALTHCARE LIMITED (IN) 2011-07-13 — — EP claimed
US-20100273791-A1 TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CADILA HEALTHCARE LIMITED 2010-10-28 — — US claimed
US-8030345-B2 Tricyclic pyrazole derivatives as cannabinoid receptor modulators CADILA HEALTHCARE LIMITED (IN) 2011-10-04 — — US disclosed
EP-2343302-A1 TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CADILA HEALTHCARE LIMITED (IN) 2011-07-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273791-A1 TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, GPR55 CNR1 2/4885CNR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback